Endovascular Treatment Devices Market Size, Share, Growth, Trends, and Global Industry Analysis: Size, Share, Growth, Trends, and Global Industry Analysis By Devices Type (Percutaneous Endovascular Aneurysm Repair (EVAR), Fenestrated EVAR, Aortic stents Biodegradable Stents, Self-expanding Nitinol Stents, Thoracic Aortic Aneurysms Grafts, and Other Devices), By Procedure Type (Balloon Angioplasty, Angioplasty with Stent Placement, Drug-Eluting Stents (DES), and Others), By Therapeutic Area (Pulmonary, Vascular, Cardiology Surgery, Neurology, and Radiology), and Region Forecast 2019-2030

Endovascular Treatment Devices Market size was valued at US$ 3,834.2 million in 2023 projected to grow at CAGR of 9.2% from 2024-2030. Endovascular treatment devices, which provide minimally invasive solutions for a range of problems, have completely changed the field of vascular medicine. These devices allow surgeons to access and treat diseased blood arteries through small incisions. The market for endovascular treatment devices is expanding rapidly due to several important considerations rising incidence of cardiovascular conditions including aneurysms and peripheral artery disease, which need sophisticated endovascular procedures for successful treatment, is one of the drivers. The market is expanding because of the growing demand for minimally invasive procedures, which have lower complication rates and recovery periods than standard surgery. There are lots of opportunities in the market, especially for the creation of cutting-edge tools and technology that enhance patient outcomes and procedural effectiveness, strict regulatory policies, and the need for considerable clinical testing.

Moreover, several endovascular devices face long-term efficacy and safety-related issues, which raise barriers to their adoption. Some of the trends being witnessed in the endovascular treatment devices market include the development of sophisticated, patient-specific solutions and the growing use of robotics to enhance precision and thereby enhance the outcomes of endovascular procedures. Additionally, the development of these durable and bioresorbable devices aims to minimize the number of long-term implants and follow-up procedures. These trends shape the future and drive innovation in the further expansion of scopes within endovascular treatments.

Endovascular Treatment Devices Market Key Developments:

• In April 2024: Getinge received EU MDR approval for its Advanta V12 covered stent system, tailored for treating patients with renal artery stenosis and aortoiliac occlusive disease, including lesions at the aortic bifurcation. This certification confirms compliance with European medical device regulations, underscoring Getinge's dedication to quality and patient safety in vascular interventions.
• In March 2023: Medtronic plc (NYSE: MDT) has FDA-approved its Evolut™ FX+ TAVR system for treating symptomatic severe aortic stenosis. This updated system retains the performance benefits of the Evolut platform and improves coronary access capabilities, offering enhanced treatment options for patients in the U.S.